Sulindac and Epirubicin in Treating Patients With Metastatic Malignant Melanoma

OBJECTIVES:

Primary

• To estimate the non-comparative efficacy of sulindac and epirubicin hydrochloride in patients with metastatic malignant melanoma.

Secondary

• To characterize the toxicity of this regimen in these patients.

OUTLINE: This is a multicenter study.

Patients receive oral sulindac 2 hours prior to receiving epirubicin hydrochloride IV over 15 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.

Previously collected tumor blocks are assessed for cancer resistance markers by IHC.

After completion of study treatment, patients are followed for 1 month, and then every 3 months thereafter.

DISEASE CHARACTERISTICS:

• Histologically confirmed malignant melanoma

• Metastatic disease
• Tumor block available for resistance marker analysis
• Measurable or evaluable disease
• No active brain metastases except for patients who have undergone successful complete excision of solitary brain metastasis

PATIENT CHARACTERISTICS:

• Karnofsky performance status 80-100%
• ANC > 1 x 10^9/L
• Platelet count > 100 x 10^9/L
• Hemoglobin > 9 g/dL
• Serum bilirubin normal (except in patients with benign congenital hyperbilirubinemia)
• Not pregnant or nursing
• Negative pregnancy test
• Normal cardiac ejection fraction, cardiac wall motion, and ECG
• No active heart disease, including any of the following:

• Myocardial infarction within the past year
• Pericarditis
• Existing hypertension requiring treatment
• No other active serious medical or psychiatric disease
• No prior or concurrent malignancy, other than basal cell carcinoma of the skin , or carcinoma in-situ of the cervix

PRIOR CONCURRENT THERAPY:

• No prior anthracycline or anthracenedione-containing chemotherapy regimen
• No prior cardiac radiotherapy
• No major surgery within the past 2 weeks
• No participation in any clinical trial within the past 4 weeks
• No other concurrent anticancer therapies

• Concurrent bisphosphonates allowed in patients with bony metastases with extra-osseous measurable or evaluable lesions
• No other concurrent experimental medications